EW
Edwards Lifesciences Corporation
October 8, 2026 · intraday
- Rarity
- 1.26
- Peak move
- −3.89%
- Float cap
- $49.1B
Edwards Lifesciences Corporation develops and sells medical technologies for structural heart disease. Its portfolio includes transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical heart valves and repair products. These therapies are used by cardiac surgeons and interventional cardiologists to treat patients with aortic, mitral, tricuspid, and pulmonic valve disease and other advanced cardiovascular conditions.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingBarclays analyst Christopher Pasquale initiated coverage of Edwards Lifesciences with an Overweight rating and a $110 price target on Oct 7, 2026, naming it a top large-cap pick alongside Stryker as part of coverage launch on 26 US medical technology companies.
earnings_releaseEdwards Lifesciences said it will report third-quarter 2026 results after market close on Nov. 4, 2026, with a conference call at 5:00 p.m. ET.
financial_regulatoryThe European Commission on Oct 5, 2026 selected Edwards Lifesciences' SAPIEN M3 Transcatheter Mitral Valve Replacement System and Highlife's trans-septal mitral valve system as the first two medical devices for Joint Clinical Assessment under the EU HTA Regulation, assessed by Dutch ZIN with Norwegian DMP as co-assessor.
analyst_ratingCiti maintained a Buy rating and $110 price target on Edwards Lifesciences while opening an 'upside 90-day catalyst watch,' citing two expected trial readouts at the Nov 2 Transcatheter Cardiovascular Therapeutics conference.
index_rebalanceEdwards Lifesciences announced it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Nov. 2, 2026, with a live Q&A with physicians and management.
regulatory_approvalCMS finalized its updated National Coverage Determination for transcatheter aortic valve replacement on Sept 10, 2026, dropping coverage-with-evidence-development requirements for symptomatic severe aortic stenosis, adding coverage for asymptomatic severe AS under CED, and eliminating hospital volume thresholds and the dual-operator requirement.